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A Universal Live Cell Barcoding-
Platform for Multiplexed Human 
Single Cell Analysis
Felix J. Hartmann1, Erin F. Simonds2 & Sean C. Bendall  1
Single-cell barcoding enables the combined processing and acquisition of multiple individual samples 
as one. This maximizes assay efficiency and eliminates technical variability in both sample preparation 
and analysis. Remaining challenges are the barcoding of live, unprocessed cells to increase downstream 
assay performance combined with the flexibility of the approach towards a broad range of cell types. To 
that end, we developed a novel antibody-based platform that allows the robust barcoding of live human 
cells for mass cytometry (CyTOF). By targeting both the MHC class I complex (beta-2-microglobulin) and 
a broadly expressed sodium-potassium ATPase-subunit (CD298) with platinum-conjugated antibodies, 
human immune cells, stem cells as well as tumor cells could be multiplexed in the same single-cell 
assay. In addition, we present a novel palladium-based covalent viability reagent compatible with this 
barcoding strategy. Altogether, this platform enables mass cytometry-based, live-cell barcoding across 
a multitude of human sample types and provides a scheme for multiplexed barcoding of human single-
cell assays in general.
In recent years, the development of high-dimensional single-cell technologies such as mass cytometry (also 
termed cytometry by time-of-flight; CyTOF) have enabled unprecedented insights into many biological and clin-
ical questions, spanning research in hematopoiesis1,2, stem cells3, cancer4–6, and autoimmunity7–9. Together with 
newly developed data analysis approaches (reviewed in refs10–13), mass cytometry and other single-cell analysis 
methodologies provide an ideal platform for explorative studies, which oftentimes involve large groups of samples 
with unknown cellular composition. In order to improve sample comparability and inter-assay reproducibil-
ity, much effort has been invested into the standardization and quality control of mass cytometry experiments. 
Changes in instrument sensitivity across different days or during extended acquisitions have been addressed 
by implementing a daily tuning procedure14 and through the simultaneous acquisition of bead standards15. To 
further minimize technical variance from experimental procedures or data analysis, multiple samples can be 
combined and processed in parallel as one single sample via cellular barcoding. For mass cytometry, individual 
samples are tagged with a unique combination of heavy-metal isotopes such that all cells of a sample are perma-
nently labeled with their respective identifier16,17. These labeled samples can then be combined into one composite 
sample for simultaneous downstream experimental handling including antibody staining, washing, fixation, and 
acquisition. Following data acquisition, individual cells can be unmixed in silico and reassigned back to their 
initial samples via their unique barcode.
First mass cytometry-specific barcoding approaches have relied on labeling cells with heavy-metals via amine- 
or sulfhydryl-reactive chelating agents16,17. As these groups are most abundantly found within cells, as opposed to 
their surface, fixation and permeabilization are required, making these methods less suitable for barcoding before 
probing of fixation- or permeabilization-sensitive molecules or epitopes.
These issues can be overcome by making use of cell-surface molecules for barcoding purposes. For instance, 
the protein tyrosine phosphatase, receptor type C (CD45) has been proposed as a candidate antigen for live-cell 
barcoding using chelated palladium isotopes18,19. Still, the varied tissue expression pattern and weak palladium 
signal limit this approach in applicability to cells highly expressing CD45, namely peripheral blood mononu-
clear cells (PMBCs). Instead, we have devised a live-cell barcoding method robust to cell origin and identity. 
To do so, we targeted a combination of ubiquitously expressed cell surface molecules with cisplatin-conjugated 
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antibodies20. We then demonstrate broad applicability of this approach in research involving human stem cells, 
immune cells as well as a broad range of different cancer cell lines and patient samples.
Results
MHC-I and sodium-potassium ATPase-subunits are broadly expressed across multiple human 
cell types. To facilitate robust barcoding of live human cells of different origin, we first identified cell surface 
proteins which were reported to be broadly expressed across different immune cell subsets, various organs21 and 
in cancer cell lines22,23. Further requirements were high epitope abundance as well as the availability of an anti-
body probe for robust detection of the target. Based on these criteria, we conjugated antibodies against beta-2-mi-
croglobulin (b2m) as part of the MHC class I complex as well as antibodies against the beta-3 subunit of the 
Na+/K+-ATPase (CD298) to heavy-metal isotopes for their use in mass cytometry (Fig. 1A). Next, we tested 
their expression on various cell populations, including immune cell subsets found in whole blood (Fig. 1B,C, see 
Table S1), as well as various cancer and non-immune cell lines such as leukemic (U937, Ramos, HEL, Jurkat, REH 
and THP-1), embryonic or stem cell-derived (293 T, H9 human embryonic stem cells (hESCs) and NTERA) and 
carcinoma cell lines (A549, NCI-H460, HCT 116 and HeLa; Fig. 1D). As expected, b2m was robustly expressed on 
all major immune cell subsets found in human whole blood. Granulocytes displayed slightly lower but still consid-
erable expression of b2m. Most cancer cell lines also expressed b2m with the exception of low or absent expression 
levels on embryonic/stem cell lines and intermediate levels on a subset of leukemia cell lines (Fig. 1D; left).
CD298 was found to be expressed with intermediate levels on all identified immune cell subsets and with 
intermediate to high levels on the analyzed cell lines, including those which showed low to negative b2m staining 
(Fig. 1C,D; middle). Dying and/or dead cells might decrease surface expression of these molecules to varying 
extent (Fig. S1). Given these expression patterns, we reasoned that the combined staining of both molecules 
with antibodies conjugated to the same reporter isotopes would not only increase the number of available 
epitopes resulting in augmented staining intensity, but also increase its robustness and facilitate barcoding of 
Figure 1. MHC-I and sodium-potassium ATPase-subunits are broadly expressed across different cell types.  
(A) The two surface proteins b2m as part of the MHC-I complex and CD298, a subunit of the sodium potassium 
pump, were selected as potential targets for live cell barcoding. (B) Human whole blood was subjected to red 
blood cell (RBC) lysis and subsequently stained with heavy-metal isotope-conjugated antibodies for mass 
cytometry (Table S1). Cells were pre-gated on live, single, CD45+ and CD235ab-. The main immune lineages 
were then identified via the indicated gating scheme. (C) Expression of b2m (light blue, left), CD298 (magenta, 
middle) and combined expression values from b2m and CD298 using the same reporter isotope (dark blue, 
right) on immune populations as in B. (D) Expression of b2m (light blue, left), CD298 (magenta, middle) and 
combined expression values from b2m and CD298 using the same reporter isotope (dark blue, right) on various 
cancer cell lines. Shown is one representative experiment out of two.
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heterogeneous samples containing multiple cell types. Indeed, combined staining of b2m and CD298 within the 
same detection channel demonstrated strong signal across all populations (Fig. 1C,D; right).
In summary, while the wide variety of cell types tested exhibited variability in their expression of b2m and 
CD298, there was no instance where the abundance of both was low at the same time, thus making their combi-
nation ideal for molecular barcoding.
Monoisotopic cisplatin-conjugated antibodies are robust across analysis conditions. To maxi-
mize the compatibility of this approach with existing mass cytometry assays, heavy-metal isotopes which are not 
part of and which do not interfere with the typically employed lanthanide range are desirable for barcoding. One 
possibility is the conjugation of EDTA-chelated palladium to antibodies18, which provided a first extension of 
the lanthanide range for antibody labeling. However, given the mass response curve of current mass cytometers, 
palladium isotopes suffer from a low detection sensitivity. Alternatively, cisplatin-based conjugation of platinum 
to antibodies has been reported to possess superior signal intensities compared to EDTA-chelated palladium anti-
bodies20. Consequently, we conjugated anti-b2m and anti-CD298 antibodies to four different platinum isotopes 
(194Pt, 195Pt, 196Pt and 198Pt) via direct, covalent binding of cisplatin (Fig. 2A). Platinum-conjugated antibod-
ies retained their initial specificity as shown by staining a mixture of CD45-positive (Jurkat) and CD45-negative 
(HeLa) cells with anti-CD45 antibodies. We did not detect any unspecific binding of platinum-conjugated 
anti-CD45 antibodies to CD45-negative HeLa cells (Fig. 2B), as had been occasionally observed with 
EDTA-chelated Pd antibodies (data not shown).
To assess the binding stability of cisplatin-antibodies to their target cells, cisplatin-antibody stained cells 
were fixed with 1.6% PFA and permeabilized using methanol (MeOH) before acquisition (Fig. 2C). Measured 
platinum-signal intensities from MeOH and non-permeabilized samples were comparable, indicating sta-
ble binding of platinum-antibodies to their target epitopes which is not majorly disrupted through standard 
Figure 2. Cisplatin-conjugation of antibodies provides a specific and stable extension to lanthanide antibodies. 
(A) CD298 and b2m antibodies were conjugated to four different platinum isotopes (194Pt, 195Pt, 196Pt and 
198Pt) via covalent binding of cisplatin. (B) Unstained Jurkat and 209Bi-stained HeLa cells were combined and 
stained with cisplatin-conjugated anti-CD45 (left) or no anti-CD45 antibody (right). (C) Cisplatin-antibody 
(anti-b2m) stained PBMCs and unstained PBMCs were mixed and acquired without (left) or after MeOH 
fixation (right). (D) Cells as in (C) were kept in intercalation solution at 4 °C for the indicated number of days 
before acquisition. (E) PBMC samples were stained with anti-b2m and anti-CD298 antibodies conjugated 
to different platinum isotopes. Numbers indicate median intensity in the respective channel (left). Median 
intensities were scaled to the maximum of the respective experiment (right).
www.nature.com/scientificreports/
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cell processing methods. Further, we assessed storage stability of platinum-antibody stained samples at 4 °C in 
PFA-based intercalation solution (Fig. 2D). We observed a slight decrease signal intensity after prolonged sample 
storage, similar to what has been reported for lanthanide-conjugated antibodies24. Importantly, even after 21 
days of storage at 4 °C, positive and negative populations could still be readily resolved. Lastly, to compare the 
sensitivity of the different platinum channels on our mass cytometer (CyTOF2), we stained samples with the 
same antibody clones conjugated to different platinum-isotopes (Fig. 2E). Measured signal intensities across the 
four platinum channels were found to be very similar, indicating that these channels have equivalent potential 
for use in mass cytometry applications, including barcoding. As such, monoisotopic cisplatin antibody conju-
gates provide a practical means for live-cell barcoding and do not interfere with lanthanide-based target protein 
measurements.
Combining b2m and CD289 for live-cell barcoding of heterogeneous human samples. Having 
identified suitable target epitopes and conjugation procedures, we combined these approaches to demonstrate 
their applicability to live cell barcoding. In order to extend the number of possible barcode combinations, we 
used indium isotope-conjugated (113In and 115In) anti-b2m and anti-CD298 antibodies in addition to four 
cisplatin-conjugated antibodies, as described above. Employing a 6-choose-3 scheme enables the barcoding of 
up to 20 samples with clear doublet identifying ability17. PMBCs from healthy donors were distributed into 20 
individual samples and barcoded by staining the individual samples with combined anti-b2m and anti-CD298 in 
three out of the six available isotopes (Fig. 3A). Barcoded cells were combined, surface-stained, fixed and MeOH 
permeabilized before acquisition on a CyTOF2 mass cytometer. Barcode-positive and negative populations were 
readily distinguishable using both cisplatin and chelator-based conjugation methods (Fig. 3B). The combined 
sample was then loaded into existing matlab-based debarcoding software17 to automatically assign cells back to 
their initial identity (Fig. 3C). Up to 95% of input cells were assigned to their respective samples, using appropri-
ate debarcoding parameters (cutoff: 0.1; Mahalanobis distance: 30). Debarcoded samples displayed the expected 
staining patterns according to their assigned barcode (Fig. 3D–E). Next, we tested the reliability and feasibility 
of barcoding different sample types, including non-immune cell subsets, into one reaction vessel. We prepared 
individual samples from human PBMCs or human epithelial HeLa cells, performed live cell barcoding, combined 
all samples into one vessel and subsequently stained for CD45 surface expression (Fig. 3F,G). To test the overall 
performance after acquisition and debarcoding we assessed the expression of CD45, a marker expected to be 
ubiquitously expressed by PBMCs but not HeLa cells. Virtually all cells (>99.5%) assigned to PBMC samples were 
found to express CD45 and vice versa, HeLa samples were not found to contain CD45+ cells (Fig. 3G). Together 
these data demonstrate that the combination of anti-b2m and anti-CD298 antibodies enables highly multiplexed, 
doublet-free live-cell barcoding of a variety of human cell types.
A novel covalent palladium-based viability staining. Platinum, via cisplatin staining, is often used as 
a viability probe in mass cytometry because of its preferential accumulation in membrane-compromised cells and 
its covalent binding properties25. As our proposed barcoding strategy (Fig. 3) makes use of all currently available 
purified platinum isotopes for antibody labeling, we examined potential alternatives for covalent viability probes. 
Given its structural similarity to cisplatin, we investigated the use of dichloro-(ethylenediamine) palladium(II) 
(termed ‘DCED-palladium’) to identify membrane-compromised (dead) cells (Fig. 4A). Mixtures of live and 
heat-killed PBMCs were stained simultaneously with cisplatin and DCED-palladium for 5 min at RT (Fig. 4A). 
Dead cells were readily identifiable by their increased binding of cisplatin compared to live cells (Fig. 4B). Further, 
while cisplatinlow cells showed negative to low signal for DCED-palladium, we found cisplatinhigh cells to have 
strong signal in the indicated palladium channels, following the naturally occurring abundance of the differ-
ent isotopes (Fig. 4B). This correlation between cisplatin and DCED-palladium binding is further confirmed 
by directly analyzing platinum and palladium signal in a co-stained, live and heat-killed cell mixture (Fig. 4C). 
Again, dead cells were found to be positive for cisplatin as well as DCED-palladium.
Lastly, we tested whether the correlation between platinum-positive and palladium-positive frequencies holds 
true in various biological sample types. We routinely co-stained multiple samples including, PBMCs, digested 
tumor- and healthy-tissue samples and cancer cell lines with both viability probes. These samples spanned a wide 
range of dead-cell frequencies and furthermore, contained samples which were permeabilized for intracellular 
staining steps with either MeOH-based protocols or commercially available transcription factor staining kits. 
Importantly, DCED-palladium provided highly comparable dead-cell identification across all sample types as 
well as the full range of dead-cell frequencies (Fig. 4D), thus indicating that it can be readily used on its own to 
replace cisplatin as a viability probe and thus allow the full use of platinum-conjugated antibodies in mass cytom-
etry experiments (Fig. 4E).
Live cell barcoding enables the interrogation of tumor-immune composition and function. 
Lastly, we employed the above-described methodology (Fig. 3 and 4) to perform live cell barcoding of an exem-
plary, clinically relevant sample: a tissue biopsy of a lung carcinoma containing a heterogeneous mixture immune 
and non-immune cells (Fig. 5A). Firstly, the tissue sample was digested to prepare a single-cell suspension. We 
independently assessed the impact of enzymatic digestion on cellular b2m and CD298 surface expression and 
found that, under these conditions, cells retained sufficiently high surface expression for robust live cell barcod-
ing (Fig. S2). Next, the sample was divided and activated for varying time periods (1–24 h) with different stimuli 
including interferon-γ (IFN-γ), lipopolysaccharide (LPS) or phorbol 12-myristate 13-acetate (PMA) and iono-
mycin, resulting in a total of 20 different conditions. Differentially stimulated samples were live-cell barcoded, 
combined and stained with heavy-metal conjugated antibodies (Table S1). After acquisition and debarcoding, 
multiple immune cell subsets but also non-hematologic cells could be identified and directly interrogated for their 
expression of immunologically important surface markers (Fig. 5B).
www.nature.com/scientificreports/
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Additionally, we automatically identified different cell lineages via the SPADE algorithm26 (see also Fig. S3), 
giving an immediate overview of stimulation-induced changes in surface protein expression on immune but also 
on tumor cells. Fold changes of protein expression induced by the indicated stimuli were overlaid on selected 
parts of the tree structure (Fig. 5C).
Using our methodology, we confirmed the well-described upregulation of the activation-associated proteins 
HLA-DR or CD69 by PMA/ionomycin on various T cell subsets, as well as LPS-induced augmented expression 
of the co-stimulatory protein CD86 on antigen-presenting cells (APCs). Importantly, in addition to the changes 
detected in immune cells, interesting observations could be made on tumor cells simultaneously, including 
well-described IFN-γ induced upregulation of HLA class I expression27, downregulation of the anti-phagocytic 
protein CD47 [ref.28] or upregulation of the programmed cell death receptor CD95, also termed FasR [ref.29] on 
these cells (Fig. 5C). Together, this demonstrates the utility of the platform we have presented here to interrogate 
heterogeneous samples such as primary human tumor and immune cell mixtures to achieve a more integrated 
view of potential cellular interactions in a setting where the limitation of technical variability is crucial.
Figure 3. CD298 and b2m enable robust live cell barcoding of heterogeneous samples. (A) Schematic 
representation of the barcoding procedure. Individual samples are barcoded with a combination of three 
different b2m and CD298 antibodies, pooled, stained and acquired. Samples can then be debarcoded using the 
supplied barcoding matrix. Arrows point out sample 10 and 13 which are used as examples in A and C. (B) 20 
PBMC samples were barcoded using the above described method. Shown are live, single cells from combined 
samples before debarcoding. (C) Combined samples can be debarcoded using existing algorithms and software. 
(D) Example of a debarcoded sample positive for three of the available six barcodes. (E) Signal intensities of  
all barcode isotopes from combined anti-b2m and anti-CD298 antibodies on debarcoded samples as in E.  
(F) PBMC and HeLa samples were barcoded, combined and stained with anti-CD45 (left). Frequency of CD45+ 
in debarcoded cells (right). (G) Exemplary biaxial plots demonstrating CD45 staining in debarcoded cells as in 
F, assigned to a PBMC (left) or HeLa sample (right).
www.nature.com/scientificreports/
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Discussion
Cellular barcoding approaches have been proposed for a variety of technologies, including single-cell sequenc-
ing30, antibody/sequencing hybrid technologies31, genetic barcoding for cell lineage tracing32, fluorescent bar-
coding for flow cytometry33 and more recently heavy-metal isotope based barcoding in mass cytometry17–19,34.
In contrast to many previous methods, our approach does not require samples to be fixed or permeabilized 
prior to barcoding and surface staining and is thus especially suited for scenarios in which target molecules 
or downstream assays are fixation- or detergent-sensitive or in cases in which this is unknown. Further, the 
above-described method is independent of CD45 expression which has been proposed for live cell barcoding of 
PBMCs before18,19. This now allows barcoding of cells of non-immune origin, including tumor cells or stem cell 
populations. Additionally, within leukocytes, CD45 expression is variable and informative for cell lineage iden-
tification. Our CD45-independent barcoding therefore circumvents elaborate methods involving pre-barcode, 
non-saturating surface staining of CD45 [ref.35] and enables easy incorporation of CD45 into the analysis panel.
Instead of CD45, we here made use of the broad expression of b2m as part of the MHC-I complex and the 
CD298 subunit of the sodium-potassium ATPase. Both proteins have been shown to be broadly expressed across 
different types of samples and biclonal barcoding using these two targets provides increased signal intensities and 
robustness against potential downregulation, e.g. on tumor cells36. Further, using this combination allowed us to 
confidently assign up to 95% of cells to individual samples, which is similar to or exceeding previously reported 
frequencies17.
Homologous protein-complexes of the human MHC-I and sodium-potassium ATPases are also expressed by 
many commonly used model organisms including mice and rats and thus, this method should be readily trans-
ferable to research questions in other species. Additionally, staining with a combination of anti-human b2m and 
CD298 antibodies could also serve to robustly identify human cell in various xenograft models23.
As aforementioned, ideal elemental isotopes for barcoding are outside of the lanthanide range typically 
reserved for the analysis panel. Therefore, we here employed four different platinum isotopes, 194Pt, 195Pt, 196Pt 
and 198Pt. Besides these, 190Pt and 192Pt occur naturally but with very low abundance and were therefore 
not available in sufficient enrichment grades, however they could become obtainable in the future. Platinum 
isotopes were conjugated to antibodies via direct binding of cisplatin which has been found to covalently react 
with cysteine residues37. Thus, conjugation does not require additional chelating-agents and chelating reactions, 
making the labeling reaction economical, rapid and uncomplicated. Antibodies are labelled analogously to famil-
iar protocols and no additional equipment is needed. Furthermore, the platinum-based barcoding ensures that 
there is no interference through isotopic impurity or oxide-formation with the lanthanide range, thus minimizing 
interaction with the analytical channels for single cell quantification. At the same time, it should be noted that 
for individuals which have received platinum-based therapeutic agents (i.e. carboplatin or cisplatin), the cellular 
background of platinum should be assessed beforehand.
Since cisplatin is often employed as a live/dead probe in mass cytometry, alternative approaches have to be 
considered when using all four commonly available platinum isotopes for antibody-based staining. The use of 
Figure 4. Palladium-based viability staining reproduces cisplatin-based dead cell identification. (A) Live 
and heat-killed (55 °C for 1 h) PBMCs were mixed and incubated for 5 min at RT with 500 nM cis-dichloro-
diamine-platinum(II) (cisplatin) and 500 nM dichloro-(ethylenediamine)-palladium(II) (DCED-palladium). 
(B) Platinum (198Pt) signal (left) in cells as in (A) was used to discriminate live (cisplatinlow) and dead cells 
(cisplatinhigh), which were then analyzed for their palladium signal in one palladium channel (110 Pd, middle) 
or across all measured palladium isotopes (right). 110 Pd is shown as an example but other Pd-channels (with 
the exception of 102 Pd) could be used analogously. Representative example from a total of n = 8. (C) DCED-
palladium (110 Pd) and cisplatin (198Pt) in cells as in (A). (D) The frequency of dead cells within multiple 
different types of samples was assessed using cisplatin and DCED-palladium simultaneously (n = 48, pooled 
from 10 independent experiments). (E) DCED-palladium on its own can be used to discriminate live from dead 
cells (here heat-killed as in A). Representative example from a total of n = 48.
www.nature.com/scientificreports/
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rhodium (103Rh) intercalator to label dead cells has been reported before38, however due to its non-covalent bind-
ing, signal-intensity is lost in downstream fixation/permeabilization and wash steps making its application less 
robust. Additionally, amine- and thiol-reactive derivatives of EDTA or 1,4,7,10-tetraaza-cyclododecane-1,4,7,10-
tetraacetic acid (DOTA) chelators have been used with non-biological metals to identify dead cells39,40. However, 
these reagents are expensive, chemically unstable, and require pre-formulation with the metal of interest. Instead, 
the here presented DCED-palladium provides a straightforward identification of dead cells in mass cytometry 
experiments. DCED-palladium is inexpensive, easy to use and store, and provides good separation between live 
and dead cell populations. Similar to cisplatin, it is compatible with downstream sample permeabilization and 
washing steps. DCED-palladium therefore provides an attractive alternative to cisplatin as a viability reagent, 
even in scenarios where cisplatin antibodies are not used for barcoding but instead to extend the analysis panel 
beyond the lanthanide range20. If needed, monoisotopic DCED-palladium could be synthesized in a relatively 
easy procedure41. Importantly, as with many reagents used in mass cytometry, DCED-palladium should be han-
dled with care so that oral and dermal contact as well as inhalation is prevented.
Figure 5. Live cell barcoding enables the combined investigation of tumor- and immune cell phenotypes and 
interplays. (A) Single-cell suspensions were prepared from a lung tumor tissue biopsy and stimulated in vitro for 
different periods of time with the indicated reagents. Tumor as well as immune cells from individual conditions 
were then live cell barcoded, combined and stained for immune-relevant markers (Table S1). (B) Different 
immune as well as tumor cell populations were identified via the indicated gating scheme and analyzed for their 
expression of multiple surface markers. APCs = antigen presenting cells. (C) Combined data was subjected 
to SPADE clustering (100 clusters) and represented as a minimal spanning tree (MST). Selected clusters are 
overlaid with a color-scheme representing the normalized fold-change in unstimulated vs. the indicated 
stimulus.
www.nature.com/scientificreports/
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Using only indium and platinum isotope-conjugated antibodies and employing the described 6-choose-3 
scheme described here, up to 20 samples can be barcoded and processed as one composite sample. However, it is 
easily possible to increase the maximum number of samples by including anti-CD298 and anti-b2m antibodies 
conjugated to other heavy metals, e.g. 89Y or 209Bi. Extending to such an 8-choose-4 scheme, up to 70 samples 
could be barcoded using this approach. As b2m and CD298 are expressed at high copy numbers per cell, the max-
imum number of multiplexing channels is virtually unlimited if one is willing to incorporate additional reporter 
metals.
As we have shown, the here described platform for live cell barcoding is especially useful for the analysis of 
samples containing heterogeneous populations, such as mixtures of tumor cells and tumor-infiltrating leukocytes. 
Given the recent success of immunotherapies using checkpoint inhibitors or CAR T cells, a huge number of clin-
ical studies is currently underway and mass cytometry is poised to be employed to identify outcome-associated 
cellular signatures, follow disease progression and predict therapeutic responses42. Especially in such settings with 
large sample numbers in which the reduction of technical variability is critical, our approach should provide sig-
nificant benefit and we thus hope that this study will contribute to further implement mass cytometry in clinical 
research.
Methods
Samples. All human samples were obtained and experimental procedures were carried out in accordance 
with the guidelines of the Stanford Institutional Review Board (IRB). Specifically, fresh whole human blood in 
heparin collection tubes or leukoreduction system (LSR) chamber contents (Terumo BCT) were obtained from 
the Stanford Blood Center. Tissue specimens were obtained from the Stanford Tissue Bank. These samples are 
generally byproducts of blood donation procedures and normal surgical pathology workflows, the collection of 
which is governed independently by the Stanford IRB. Written informed consent was obtained from all donors. 
The experimental procedures/protocols in combination with the samples used in this study were deemed human 
subject research exempt under Stanford IRB protocol #42195 which was reviewed by Stanford IRB panel IRB-98.
PBMCs were isolated via Ficoll (GE Healthcare) density gradient centrifugation and cryopreserved in fetal 
bovine serum (FBS, Omega Scientific) supplemented with 10% DMSO (Sigma). After freezing, samples were 
stored in liquid nitrogen. For tissue, single-cell suspensions were prepared using the MACS tumor dissocia-
tion kit (Miltenyi Biotec) according to the supplier’s recommendations. For experiments, cells were thawed 
by dropwise addition of pre-warmed RPMI-1640 (life technologies), supplemented with 10% FBS and 1x 
L-glutamine (Thermo Fisher) and washed twice. Whole blood was subjected to RBC lysis using 1x RBC lysis 
buffer (BioLegend), following the manufacturer’s instructions. Cell numbers were determined using an auto-
mated cell counter (TC20, BioRad).
Cell Culture. Jurkat, U937, Ramos, HEL, Reh, THP-1 and NCI-H460 cells were cultured in RPMI-1640 
supplemented with 10% FBS, 1x L-glutamine and 1x penicillin/streptomycin (Thermo Fisher). HeLa and 293 T 
cells were cultured in DMEM (Corning) supplemented with 10% FBS and 1x penicillin/streptomycin. NTERA 
cells were cultured in DMEM supplemented with 20% FBS and 1x penicillin/streptomycin. A549 were cultured 
in F-12K Medium (Thermo Fisher) and HCT 116 cells in McCoy’s 5a Medium (Thermo Fisher), both supple-
mented with 10% FBS, 1x L-glutamine and 1x penicillin/streptomycin. H9 hESCs were cultured feeder-free in 
StemMACS iPS Brew (Miltenyi Biotec) on a Matrigel Membrane Matrix (Thermo Fisher). All cell lines were 
cultured at 37 °C, 5% CO2. For sample collection, adherent cell lines were washed with PBS, dissociated by adding 
Accumax (Thermo Fisher) for 5 min at 37 °C and subsequently washed in their respective medium. Cells from 
cancer cell lines were fixed with 1.6% PFA in PBS (Electron Microscopy Sciences) for 10 min at RT and stored at 
-80 °C.
Heavy-metal conjugation of antibodies. Conjugation of anti-human antibodies to heavy metal isotopes 
of the lanthanide series and indium was conducted using the MaxPar X8 antibody-labelling kit (Fluidigm) fol-
lowing the manufacturers recommendations. Where available, pre-conjugated antibodies were obtained from 
Fluidigm. Cisplatin-conjugation of antibodies was based on a previous report20. In short, 1 mM stock solutions of 
isotopically enriched cisplatin in DMSO (custom order, Fluidigm) was pre-conditioned for 48 h at 37 °C [ref.43] 
and afterwards stored at -20 °C. Antibody buffer exchange was performed by adding 100 μg anti-human b2m 
(clone 2M2) or anti-CD298 (clone LNH-94, both BioLegend) to a 50 kDa MWCO microfilter (Milipore) and 
centrifuging for 10 min, 12,000 g at RT, followed by a second wash with R buffer (Fluidigm). Antibodies were then 
reduced with 4 mM TCEP (Thermo Fisher) for 30 min at 37 °C and washed two times with C buffer (Fluidigm). 
20 μl of the 1 mM monoisotopic cisplatin solution (equivalent to 20 nmol) was diluted in 1 ml of C buffer and 
added to the antibody in a 1.6 ml tube for 1 h at 37 °C for conjugation. Cisplatin-conjugated antibodies are then 
washed four times with 400 μl W buffer (Fluidigm) and the antibody is collected by two centrifugations (2 min, 
1,000 g, RT) with 50 μl of W buffer with an inverted column into a new 1.6 ml collection tube. Protein content 
was assessed by NanoDrop (Thermo Fisher) measurement, antibody stabilization buffer (Candor Bioscience) was 
added to a final volume of at least 50 v/v % and antibodies were stored at 4 °C.
Live cell barcoding. Individual samples of up to 3 × 106 cells each were stained with combinations of platinum 
or indium-conjugated anti-b2m (1 µg/ml) and anti-CD298 (2 µg/ml) in cell staining medium (CSM: PBS with 
0.5% BSA and 0.02% sodium azide (all Sigma)) for 30 min at RT. As described previously17, a 6-choose-3 scheme 
was used to ensure doublet identification and removal. Cells were washed twice with CSM and combined into a 
single reaction vessel for downstream staining and acquisition.
Viability staining. DCED-palladium or cisplatin (both Sigma) was resuspended in DMSO, pre-conditioned 
for 48 h at 37 °C and stored at -20 °C. Pre-dilutions were made in PBS and stored at 4 °C for up to two weeks. 
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Viability staining was performed by resuspending the sample in 1 ml of PBS and adding DCED-palladium to a 
final concentration of 500 nM, followed by incubation for 5 min at RT and washing with CSM.
Staining procedure. All surface staining was performed in CSM for 30 min at RT. Where indicated, cells 
were fixed with 1.6% PFA in PBS for 10 min at RT and permeabilized with MeOH for 10 min on ice. Before acqui-
sition, samples were resuspended in intercalation solution (1.6% PFA in PBS, 0.02% saponin (Sigma) and 0.5 μM 
iridium-intercalator or 0.5 μM rhodium-intercalator (both Fluidigm)) for 1 h at RT or overnight at 4 °C.
Data acquisition. Before acquisition, samples were washed once in CSM and twice in ddH2O. All samples 
were filtered through a cell strainer (Falcon) and resuspended at 1 × 106 cells/mL in ddH2O supplemented with 
1x EQ four element calibration beads (Fluidigm) and finally acquired on a CyTOF2 mass cytometer (Fluidigm). 
Barcoded samples were acquired using the Super Sampler injection system (Victorian Airship).
Data pre-processing and debarcoding. Acquired samples were bead-normalized using matlab-based 
software as described previously15. Normalized data was then uploaded onto the Cytobank analysis platform44 to 
perform initial gating on single, live cells based on their DNA content, their event_length parameter and the live/
dead probe. Data was transformed with an inverse hyperbolic sine (arcsinh) transformation with a cofactor of 5. 
Where applicable, barcoded data was debarcoded using matlab-based software with the reported parameters17. 
Debarcoding parameters were adjusted to match the barcoding separation of the respective experiment.
Data analysis and figure preparation. Basic gating and expression analysis was performed using the 
Cytobank environment. SPADE representations were created in Cytobank using the available implementation. 
Further downstream analysis was performed within the R software package45. Figures were prepared with bioren-
der software and Illustrator (Adobe).
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